All News
No Special Heart Risk With JAK Inhibitors, Study Finds
d
MedPage Today
Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry data indicated.
Read Article
Intravenous Immune Globulin in Dermatomyositis
Few drugs have been studied well in the treatment of dermatomyositis (DM) and only recently has intravenous immune globulin (IVIG) been granted FDA approval for the treatment of DM, based on this pivotal trial.
Read Article
Single center use IL-23 inhibitors (Guselkumab, Tildrakizumab, Risankizumab) in 80 PsA pts shows 1 yr survival 81%, w/ mean survival 61 wks (despite 95% Rx ≥1 prior biologics). 64% had PASI ≤2 at wks 12-17 and nearly 41% w/ PsA remission https://t.co/woDXhL44d5 https://t.co/6fvjzGlMEY
Links:
Dr. John Cush RheumNow ( View Tweet)
Record a Question or Comment...
Rheums: Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/rICbSJzPbk https://t.co/VIjlR6xlwQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib shows promise in scleroderma
https://t.co/6qUGLlztBd https://t.co/Mk2x2HAkiO
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.
https://t.co/EGXslouPmC https://t.co/UVcdjzbxYp
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib in 15 pts w/ early diffuse skin Scleroderma. Tofa downregulated STAT3 (macrophages, DCs) & IFN (fibroblasts) & MYOC/CCL19 (adventitial fibroblasts); well tolerated & trend to improved mRSS scores (ns) https://t.co/givh5j3m9z https://t.co/ms97tvQy5e
Links:
Dr. John Cush RheumNow ( View Tweet)
Comprehensive full-read review of #Baricitinib trials in treating COVID-19. 24 studies (16 retrospective, 5 prospective, 3 case control) studies & 3 larged RCTs show Bari as 24-38% better than comparators/SOC (few showed no change in mortality) https://t.co/2svMMX4wDw https://t.co/zoSGGZJYui
Links:
Dr. John Cush RheumNow ( View Tweet)
8 pts w/ Refractory Skin Dermatomyositis Rx w/ open label APREMILAST, @ 3 mos 7/8 pts responded w/ drop in CDASI (-12.9 pts; P < .001). Skin Bx showed downregulation of multiple inflamm pathways (STAT1/3, IL-4), IL-6, IL-12, IL-23, IFNγ & TNFα) https://t.co/mLElrRgFF1 https://t.co/4eidnPYdXJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Transitioning JIA to Adult Care is Problematic
Juvenile idiopathic arthritis (JIA) may start in adolescence and extend into adulthood.
This report shows that rheums need to develop "transition" practices to avoid a gap in healthcare.
https://t.co/DV8BZjcP5e https://t.co/e1rFXWSmXN
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid Arthritis Patients Need to Quit Smoking ASAP
A report from an early arthritis registry shows that current smoking increases disease activity and lowers health-related quality of life.
https://t.co/04WeK1OlRw https://t.co/yjZQdsrKsH
Links:
Dr. John Cush RheumNow ( View Tweet)
The University Of Pennsylvania has recv a $50 Million Gift (from Stewart & Judy Colton) to further develop the Autoimmune Disease Research program at Penn’s Colton Center for Autoimmunity. 6.4% of women and 2.7% of men have autoimmune disease https://t.co/7kdTiZnmiD https://t.co/5yXZTzmRM0
Links:
Dr. John Cush RheumNow ( View Tweet)
Causes of Death in Lupus
The California Lupus Surveillance Project has longitudinally followed included SLE cases and shown that overall, the leading cause of death was CVD, followed by rheumatic disease and hematologic/oncologic conditions.
https://t.co/XRtD2Rr77j https://t.co/fzVGSeQGQu
Links:
Dr. John Cush RheumNow ( View Tweet)
2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/sR2OMNtxAk https://t.co/qOdMEZheFz
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.
https://t.co/eHKx2D0kKp https://t.co/UdC0k3hlmX
Links:
Dr. John Cush RheumNow ( View Tweet)
20% of SLE pregnancies end w/ adverse preg outcome (APO). Use of LASSO & Machine learning of PROMISSE data (385 pt) before wk 12 could predict APO based on BP Meds, low Plts, Dz activity, and LAC (AUC=0.78) https://t.co/DZJ9UCpwCk https://t.co/5yYgj9g0dP
Links:
Dr. John Cush RheumNow ( View Tweet)
Physician Burnout Rising
The NY Times has reported results of a study showing that nearly 2/3 of doctors are experiencing at least one symptom of burnout, with a marked increase since the onset of the pandemic.
https://t.co/EGDezgyQ9e https://t.co/TmG01Un191
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatology Salaries and Career Choices
A recent doximity report shows how rheumatology salaries increase by years in practice.
https://t.co/Fmzq5zv3yp https://t.co/5Ju7ABiK2m
Links:
Dr. John Cush RheumNow ( View Tweet)
Opioid Crisis Costs USA $1.5 Trillion
Reuters has reported the results of a Congressional report showing the economic toll of the opioid addiction and overdose crisis on the United States reached nearly $1.5 trillion in 2020 alone and is likely to grow.
https://t.co/n2FC75hpDt https://t.co/UHTOMUDP5Q
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib in 15 pts w/ early diffuse skin Scleroderma. Tofa downregulated STAT3 (macrophages, DCs) & IFN (fibroblasts) & MYOC/CCL19 (adventitial fibroblasts); well tolerated & trend to improved mRSS scores (ns) https://t.co/Vt25ui8GwF https://t.co/chKZt6dvaO
Links:
Dr. John Cush RheumNow ( View Tweet)
